However, there still remains a role for adjuvant IFN-α in the setting of BRAF wild-type melanomas and in patients at increased risk of cancer immune escape or autoimmune events with CTLA-4 and PD-1 blocking antibodies. Here, IFNA2 is linked to melanoma.